Key Highlights

  • The all-time-high screen lists Amgen (NASDAQ:AMGN) at USD 478.48, a 3.73% advance during the November 4, 2026 trading day. Relative Volume reads 1.75 and Market Value sits near USD 258.68 billion. Screen figures are unverified.
  • Results for the third quarter of 2026, published after the November 3 close, showed Revenue of USD 10.4 billion (up 8%) and non-GAAP EPS of USD 6.45 (up 14%).
  • Full-year 2026 revenue guidance was lifted to a range of USD 38.9 billion through USD 39.7 billion, replacing USD 38.2 billion through USD 39.4 billion, while non-GAAP EPS now runs from USD 22.90 to USD 23.70.
  • Growth from Repatha (up 37% to USD 1,085 million), EVENITY (up 39%) and TEZSPIRE (up 43%) outweighed biosimilar losses at Prolia and XGEVA.

Product Breadth Behind the Record Move

The stock advanced 3.73% after the company published its figures the prior evening. Product sales reached USD 9,883 million, an 8% rise attributed mainly to volume instead of price. GAAP EPS climbed 19% to USD 7.08, while non-GAAP EPS gained 14% to USD 6.45. Both ends of the full-year revenue range moved up by USD 0.7 billion, and both ends of the non-GAAP EPS range by USD 0.60. Repatha generated USD 1,085 million, EVENITY USD 751 million, TEZSPIRE USD 538 million and BLINCYTO USD 496 million. The newer IMDELLTRA rose 128% to USD 406 million and UPLIZNA surged 191% to USD 451 million. The spread of gains suggests growth is not tied to a single product. Including other revenue, the Top Line totaled USD 10.4 billion, 8% higher than a year earlier, and the GAAP Operating Margin improved 9.9 points to 37.5%.

Biosimilar Erosion Absorbed While the Obesity Pipeline Advances

Amgen is absorbing a familiar drag: Prolia sales dropped 45% to USD 632 million and XGEVA sales fell 47% to USD 288 million as biosimilar rivals gained share, yet total product sales still advanced 8%. Reaching a record while absorbing that erosion suggests investors believe the growth portfolio is big enough to carry the business. The obesity candidate MariTide offers a longer-dated argument. Several Phase 3 studies are underway, and the cardiovascular, obesity and sleep apnea studies have finished enrolling while weight management studies continue. No readout is due this quarter, though the program may support a richer valuation. The screen shows a multiple of 27.75 against trailing EPS of USD 17.24, with EPS growth of 33.31%, both unverified. The quarterly Dividend stands at USD 2.52 per share, 6% above a year earlier, and management capped 2026 share repurchases at USD 3.0 billion, leaving room to return more cash later in the year.

Lower Free Cash Flow, Heavy Debt and Pricing Pressure

Working capital shifts pulled free Cash Flow down to USD 3.7 billion from USD 4.2 billion, a figure the fourth quarter will need to address. Debt totals USD 54.0 billion while cash is USD 13.2 billion, and the company bought back no stock during the quarter. Drug pricing rules remain a sector hazard, and the sharp November 5 sell-off, its worst since April 2025, illustrates how quickly mood can reverse. Anyone following Amgen (NASDAQ:AMGN) should track MariTide trial news, how fast Prolia and XGEVA erode, and whether growth in the neighborhood of 8% from volume persists into 2027. Capital Expenditure is projected at roughly USD 2.6 billion for 2026, earmarked for production capacity for recent medicines.

Where Things Stand

Amgen hit a record following a 3.73% gain, powered by third-quarter revenue of USD 10.4 billion, product growth of 8% largely from volume, and a higher 2026 outlook. Gains from Repatha, EVENITY, TEZSPIRE and recent launches have outweighed biosimilar declines. Weaker free cash flow, heavy Leverage and drug pricing rules are the principal concerns.